In this issue:
High discordance rate in assessing SN positivity in cutaneous melanoma
MBM presentation, treatment and outcomes
Active surveillance of patients who have SN positive melanoma
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy
Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1 due to CR
Risk factors for melanoma by anatomical site
Delayed irAE with anti-PD-1-based immunotherapy in melanoma
Impact of the time interval between primary melanoma excision and SLN biopsy
Validation of CP-GEP for predicting SLN metastasis in primary cutaneous melanoma
Please login below to download this issue (PDF)